Form 4: Castle Biosciences CCO Exercises Options, Sells Shares

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, exercised stock options and immediately sold 4,693 shares of common stock for a weighted-average price of $35.58 per share.

Summary

• Chief Commercial Officer Tobin W. Juvenal exercised 4,693 stock options at an exercise price of $3.38 per share.
• Simultaneously, Juvenal sold 4,693 shares of common stock at a weighted-average price of $35.58 per share, with individual trades ranging from $35.40 to $35.85.
• These transactions were conducted pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024.
• Following these transactions, Juvenal directly owns 84,595 shares of common stock.
• An additional 2,230 shares are indirectly held by the Tobin W and Susan M Juvenal Family Revocable Trust, where Juvenal and his spouse serve as trustees and beneficiaries.
• The stock options exercised were fully vested and had an expiration date of March 12, 2029.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (exercise of options and subsequent sale of shares) conducted under a pre-arranged 10b5-1 plan. This type of transaction is generally neutral in sentiment as it reflects an officer monetizing vested equity rather than a specific positive or negative operational event for the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a planned monetization of vested equity rather than an opportunistic sale.
• The officer realized a significant gain from the exercise of options, with an exercise price of $3.38 compared to a weighted-average sale price of $35.58.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a Chief Commercial Officer, reflecting the monetization of vested equity, which is a common practice for executives across various industries. The use of a Rule 10b5-1 plan indicates a pre-planned transaction, aligning with standard corporate governance practices for insiders.

Related Party Transactions

• 2,230 shares of common stock are held indirectly by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the Reporting Person and his spouse are trustees and beneficiaries.

Stakeholder Impact

• Shareholders: May observe an officer monetizing vested equity, which is a common practice and was pre-planned under a Rule 10b5-1 plan, generally not signaling a change in company fundamentals.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Tobin W. Juvenal, Chief Commercial Officer, 10b5-1 Plan